Log in
Sign up free

Home
Sectors
Earnings
IPOs
Splits

Example searches

AAPL 10-K FY2019
Visa 10-Q
shopify
renewables AND wind 8-K 6-K NOT TAC
cryptocurrency OR "blockchain technology" OR bitcoin 2018-2021

CANF Dashboard CANF
Data Charts Data
Institutional Ownership Data Ownership
ESG ESG
All Filings Filings
6-K Filing 6-K

CANF Can-Fite Biopharma 6-K2021Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer

8 Jan 21

Files SEC

6-K Current report (foreign)
99.1 Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer

Content Analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability

CANF 6-K Filings

8 Jan 21 Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer
15 Dec 20 Report of Foreign Private Issuer
14 Dec 20 Can-Fite Reports on Progress with its Namodenoson NASH Program
9 Dec 20 Report of Foreign Private Issuer

Filing View

Default size S M L
Default font Times Arial

Search this filing

All

Tables only

Footnotes only

Pre-defined:

Table of Contents

Get all this for free

Email alerts for new filings that match keywords or companies
Plot, compare & download financial data
10-K & 10-Q redlined comparisons
Advanced filing search & analysis
Sentiment analysis for financial filings
Favorites, search history, and more…

Sign up for free now More benefits

Top CANF

Log in
Sign up
Benefits
Help
Contact
Terms
Privacy

© 2021 Eighty-Five Technologies Inc. Not affiliated with SEC EDGAR.